MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from common
stock issued under...
$4,759K
Proceeds from exercise of
stock options, net
$1K
Net cash provided by
financing activities
$4,423K
Canceled cashflow
$337K
Net increase in cash
and cash...
-$10,435K
Canceled cashflow
$4,423K
Trade and other
receivables, net
-$10,896K
Share-based compensation
$2,318K
Amortization of debt issuance
costs and discounts
$2,286K
Issuance of warrants
$916K
Depreciation, amortization,
and impairment
$113K
Other, net
-$6K
Payments for taxes on
share-based compensation,...
$329K
Repayment of debt
principal including lease...
$8K
Net cash used for
operating activities
-$14,806K
Canceled cashflow
$16,535K
Net cash used for
investing activities
-$52K
Accounts payable
-$17,973K
Net loss
-$8,057K
Accrued expenses and
other liabilities
-$2,803K
Inventories
$1,896K
Prepaid expenses and
other assets
$340K
Deferred revenue
-$272K
Capital expenditures
$52K
Back
Back
Cash Flow
source: myfinsight.com
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)